Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4081
Source ID: NCT04222686
Associated Drug: Perindopril Arginine
Title: Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients
Acronym: CARE-PLP
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Perindopril Arginine|DRUG: Losartan Potassium
Outcome Measures: Primary: Variation of exercise-induced urinary albumin excretion, Variation of exercise-induced urinary albumin excretion (mg/j) between week 0 and week 8. By nephelometry method., 8 weeks | Secondary: Change in rest urinary albumin excretion, Change in rest urinary albumin excretion (mg/l) from baseline to week 08. By nephelometry method., 8 weeks|Change in mitral E/Ea ratio, Change in mitral E/Ea ratio from baseline to week 08. By tissue doppler on echocardiography., 8 weeks|Change in nycthemeral blood pressure profile (mmHg), Change in nycthemeral blood pressure profile from baseline to week 08. By using Arterial Blood Pressure Monitoring., 8 weeks|Change in concentration of antioxidants markers (micromol), Change in concentration of antioxidants markers from baseline to week 08. By spectrophotometer, 8 weeks|Change in lipid profile (triglycerides, Total cholesterol, HDL-cholesterol, LDL-cholesterol) on g/l, Change in lipid profile from baseline to week 08. By spectrophotometer, 8 weeks|Change in uricemia concentration, Change in uricemia concentration (mg/l) from baseline to week 08. By spectrophotometer, 8 weeks
Sponsor/Collaborators: Sponsor: Yaounde Central Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 23
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2017-12-20
Completion Date: 2018-04-30
Results First Posted:
Last Update Posted: 2020-01-10
Locations: Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon
URL: https://clinicaltrials.gov/show/NCT04222686